Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic Wistar rats.
The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.
Shinozaki
Tomokazu
T
Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Kimura
Masaki
M
Hosoyamada
Makoto
M
Shibasaki
Toshiaki
T
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D004435:Eating / Q000187:drug effects*; D016666:Fluvoxamine / Q000494:pharmacology*; D006963:Hyperphagia / Q000523:psychology*; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D008297:Male; D009478:Neuropeptide Y / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D015430:Weight Gain / Q000187:drug effects*
D018687:Antidepressive Agents, Second-Generation; D009478:Neuropeptide Y; D016666:Fluvoxamine